Request Sample Inquiry
Immuno-oncology Clinical Trials Market

Immuno-Oncology Clinical Trials Market

Immuno-Oncology Clinical Trials Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

150

Base Year:

2022

Date

Sep - 2023

Format:

PDF XLS PPT

Report Code:

VMR-2267

Segments Covered
  • By Phase By Phase Phase I, Phase 2, Phase 3, Phase 4
  • By Design By Design Interventional Trials, Observational Trials, Expanded Access Trials
  • By Indication By Indication Solid Tumors, Hematological Cancer, Other Indications
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 5.8 Billion
Revenue 2030Revenue 2030: USD 18.1 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 15.3%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
Sr. No. Offering Report Coverage
1. Market Size In terms of Revenue (USD Million)
2. Historic Data 2017 to 2021
3. Forecast Data 2023 to 2030
4. Market Drivers, Restraints, Opportunities, & Regional Market Trends Yes
5. Market Attractiveness Analysis Yes
6. Segment Analysis Maximum Segments
7. Regional Coverage 5 Regions
8. Country Coverage Top 22 Countries
9. Competitive Landscape and Company Market Share Analysis Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles.
10. Porter’s Five Forces Analysis Yes.
11. Value Chain Analysis Yes
12. PEST Analysis Yes
13. Regulatory Landscape Yes
14. Technology Landscape Yes
15. COVID-19 Impact Analysis Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics.
16. Top startups to watch out for Yes
17. Top 3 Trends to Watch Yes
18. Top 3 Strategies Followed by Major Players Yes
19. Top 3 Predictions by Vantage Market Research Yes
20. Discussion Guide Yes
21. Key Primary Respondents - VERBATIM Yes
22. Transcripts from the Primary Respondents Additional Cost USD 1,000
23. Others/Miscellaneous
FAQ
Frequently Asked Question
  • The global Immuno-Oncology Clinical Trials valued at USD 5.8 Billion in 2022 and is expected to reach USD 18.1 Billion in 2030 growing at a CAGR of 15.3%.

  • The prominent players in the market are ICON PLC (Ireland), IQVIA Holdings Inc. (U.S.), Covance (U.S.), BioNTech (Germany), IO Biotech Medical (Denmark), Medpace (U.S.), Novartis (Switzerland), Exscientia (UK), Syneous Health (U.S.), AstraZeneca (UK).

  • The market is project to grow at a CAGR of 15.3% between 2023 and 2030.

  • The driving factors of the Immuno-Oncology Clinical Trials include

    • Changes in lifestyle brought on by urbanization

  • North America was the leading regional segment of the Immuno-Oncology Clinical Trials in 2022.